Solvonis Therapeutics (LSE:SVNS) OCF Margin %: 0.00% (As of Dec. 2025)


What is Solvonis Therapeutics OCF Margin %?

Solvonis Therapeutics LSE:SVNS +5.00% OCF Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 3,031 Industrial Products companies, Solvonis Therapeutics ranks worse than 32992.38% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Solvonis Therapeutics's Cash Flow from Operations for the six months ended in Dec. 2025 was £-2.26 Mil. Solvonis Therapeutics's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Solvonis Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Solvonis Therapeutics's current OCF Yield % is -28.62%.

The historical rank and industry rank for Solvonis Therapeutics's OCF Margin % or its related term are showing as below:


During the past 8 years, the highest OCF Margin % of Solvonis Therapeutics was -31.92%. The lowest was -1931.03%. And the median was -210.90%.

LSE:SVNS's OCF Margin % is not ranked *
in the Industrial Products industry.
Industry Median: 6.96
* Ranked among companies with meaningful OCF Margin % only.

Solvonis Therapeutics OCF Margin % Related Terms

Solvonis Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Solvonis Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solvonis Therapeutics OCF Margin % Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial -31.92 -435.42 -210.90 0.00 0.00

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -99.42 0.00 0.00 0.00 0.00

Solvonis Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Solvonis Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.273/0
= %

Solvonis Therapeutics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.259/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Solvonis Therapeutics (LSE:SVNS) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3031 companies in the Industrial Products industry.
Is Solvonis Therapeutics' OCF Margin % too high?
Solvonis Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 3031 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' OCF Margin % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #999999 out of 3031 companies for OCF Margin %. This places Solvonis Therapeutics in the lower half of its industry. The industry median OCF Margin % is 6.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for an Industrial Products company?
The median OCF Margin % among Industrial Products companies is 6.96, based on 3,031 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median OCF Margin % is 6.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (LSE:SVNS) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.00 — trading 91.6% below its estimated fair value. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Solvonis Therapeutics (LSE:SVNS), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solvonis Therapeutics Business Description

Other Exchanges J4I:Germany
Address Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.